We are pleased to announce that the Metapain® study has enrolled its first patient in Russia, reaching a total of one-hundred patients enrolled so far in Europe.
Metapain® is a comparative, randomized, double-blind, 3-arm parallel, phase III study to evaluate the efficacy and safety of an oral Fixed Dose Combination of two non-opiate synergistic analgesics to alleviate moderate to severe pain.